YaHai Biotech, rooted in the frontiers of life sciences and molecular biology, is committed to continuously expanding its depth and reach in precision medicine, gene therapy, and public health applications. Our vision is to build an integrated precision genomics platform that unifies genetic testing, data analysis, and therapeutic intervention—delivering a full life-cycle health solution that spans “detection–early warning–intervention–monitoring.”

In the field of genetic testing, we aim to accelerate the development of high-throughput, low-cost, and accessible genetic screening products—enabling earlier risk prediction, more precise drug matching, and stronger protection of family lineage information.

In the field of gene therapy, our focus lies in advancing the clinical translation of viral RNA vector delivery systems and gene editing tools such as CRISPR-Cas9. We strive to break through current treatment bottlenecks for monogenic diseases, cancer, and rare disorders, driving a strategic shift from disease management to potential cure.

At the same time, we will promote the deep integration of bioinformatics, artificial intelligence, and genomic data to build a visualized and intelligent personal health risk management platform, serving medical institutions, research centers, and government public health decision-making.

Looking ahead, YaHai Biotech is dedicated to becoming a global leader in genetic innovation and a trusted partner in health services. Through technological innovation, we aim to empower life management; through inclusive principles, we advocate for health equity—so that everyone can enjoy a longer, healthier, and more controllable life in the genomic era.